Breast cancer drug approved for new indication.
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D017277:Drug Approval; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000077341:Lapatinib; D000077289:Letrozole; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D009570:Nitriles / Q000008:administration & dosage; D017698:Postmenopause / Q000187:drug effects; D011799:Quinazolines / Q000008:administration & dosage*; D014230:Triazoles / Q000008:administration & dosage; D014481:United States; D014486:United States Food and Drug Administration; D016387:Women's Health
D000970:Antineoplastic Agents; D009570:Nitriles; D011799:Quinazolines; D014230:Triazoles; D000077341:Lapatinib; D000077289:Letrozole